



Pharmacy Quality Assurance Commission
PO Box 47852 Olympia, WA 98504
www.doh.wa.gov · TDD Relay: 711

To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email doh.information@doh.wa.gov.

February 14, 2025 Weekly Legislative Review Agenda

Time: 12:00 p.m. – 1:00 p.m.
Location: Zoom ID: **890 1330 6617**
<https://us02web.zoom.us/j/89013306617>
Or One tap mobile :
+12532050468,,89013306617# US
+12532158782,,89013306617# US (Tacoma)
<https://zoom.us/join>
Webinar ID: 890 1330 6617
In Person: Department of Health, TC2
[111 Israel Rd SE, Rm. 140](#)
[Tumwater, WA 98501](#)
Contact: Joshua Munroe, Rules and Legislative Consultant, 360.502.5058
Joshua.Munroe@doh.wa.gov
Commission Office: wspqac@doh.wa.gov

No registration needed. **All attendees will join the call with their audio connection muted.**

12:00 p.m.

1. Call to Order
 - 1.1. Roll Call
2. PQAC Bill Report
3. Public Comment Period

1:00 PM (approximately)
Meeting Adjourned

[Link to Washington State Legislature Bill Information 2025](#)

Monday, January 13 – First day of session
 Friday, February 21 – Policy committee cutoff **Next cutoff**
 Friday, February 28 – Fiscal committee cutoff
 Wednesday, March 12 – House of origin cutoff

Wednesday, April 2 – Policy committee cutoff (opposite house)
 Tuesday, April 8 – Fiscal committee cutoff (opposite house)
 Wednesday, April 16 – Opposite house cutoff
 Sunday, April 27 – Sine die: Last day allowed for regular session under state constitution

TVW - <http://www.tvw.org/>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
HB 1849	Unexpired prescription drug donation program eligibility	This bill amends RCW 69.70.050 to change the eligibility conditions for drugs donated to the unexpired prescription drug donation program. The bill strikes the requirement that qualifying donated prescription drugs bear an expiration date more than six months after the donation date, and replaces it with a requirement that the drug is not expired at the time of donation and there is “sufficient time” prior to the drug’s expiration for it to be used by another individual.	HB 1849 <i>Sponsor(s):</i> Representatives Graham, Griffey, Stuebe, Keaton, Volz, Eslick, and Obras <i>First Reading (House):</i> 2/5/2025, referred to Health Care & Wellness Committee.
HB 1850	Replacement of continuous glucose monitoring equipment	This bill would require pharmacies that dispense continuous glucose monitoring equipment maintain a sufficient supply of monitoring sensors for patients that utilize such equipment. Pharmacies with physical locations that dispense such equipment would need to provide a same-day replacement for patients in need of an additional sensor due to equipment malfunction or emergency. Mail-order pharmacies would need to provide a sensor replacement “promptly,” meaning they must mail a replacement no later than the next business day. If the mail-order pharmacy cannot mail out by the next business day, they must send out the sensor “as soon as practicable.”	HB 1850 <i>Sponsor(s):</i> Representatives Graham, Burnett, Griffey, Volz, Eslick, and Obras <i>First Reading (House):</i> 2/5/2025, referred to Health Care & Wellness Committee.

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
HB 1725	Biosimilar product access	<p>The purpose of the bill is to remove barriers that restrict access to FDA-approved biosimilar drug products. RCWs 48.43.420(10) and 41.05.410(2)(j) are amended to add biosimilars as an option available to health plans. Biosimilars are also included as an option pharmacists must use to replace a prescribed biological product as a cost-saving measure, per amended language in RCW 69.41.125.</p> <p>Section 4 of the bill amends RCW 69.41.120 and removes therapeutically equivalent generic drug substitutions and adds substitution provisions for biosimilars as defined under 42 U.S.C Sec. 262(i)(2) in place of a trade or brand name drug product when filling a prescription order, unless a practitioner explicitly communicates that a substitution is not allowed. The selection of which biosimilar or interchangeable biological drug product to dispense is at the discretion of the pharmacist, but the same responsibility is assumed for dispensing the biosimilar as for the prescribed drug product, and the pharmacist may not select a drug unless it costs the patient less than the prescribed drug product. Pharmacists must communicate substitutions to the patient using the name of the dispensed drug product indicated on the prescription label.</p>	<p>HB 1725 <i>Sponsor(s):</i> Representatives Thai, Shavers, Parshley, Duerr, and Macri</p> <p><i>First Reading (House):</i> 1/30/2025, referred to Health Care & Wellness Committee <i>Public Hearing (Health Care & Wellness):</i> 2/12/2025</p>
SB 5594	Biosimilar product access	<p>The text of this bill is nearly the same as that in HB 1725 on the topic of biosimilar drug product use, with the exception of some language choices in Sections 4 and 5.</p>	<p>SB 5594 <i>Sponsor(s):</i> Senators Harris and Cleveland</p> <p><i>First Reading (Senate):</i> 1/30/2025, referred to Health & Long-Term Care Committee. <i>Public Hearing (Health & Long-Term Care):</i> 2/11/2025</p>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
HB 1720	Types of medication assistance in community-based care settings	This bill amends the definition of “medication assistance” in RCW 69.41.010(15) for the purpose of expanding the actions available to nonpractitioners providing medication assistance to individuals residing in a community-based or in-home care setting. Nonpractitioners would be allowed to set up diabetic devices for self-administration and would also be allowed to hand injectable medications to an individual for self-administration.	HB 1720 <i>Sponsor(s):</i> Representatives Schmick and Low <i>First Reading (House):</i> 1/29/2025, referred to Health Care & Wellness Committee. <i>Public Hearing (Health Care & Wellness):</i> 2/11/2025 <i>Executive Session (Health Care & Wellness):</i> 2/12/2025
HB 1638	Good Faith Pain Act	This bill establishes protections for various health care professions “acting in good faith” in prescribing or dispensing opioid drugs “for legitimate medical purposes in the course of professional practice.” The covered professions include pharmacists, dentists, physicians, physician assistants, advanced registered nurse practitioners, podiatric physicians and surgeons, and osteopathic physicians and surgeons.	HB 1638 <i>Sponsor(s):</i> Representative Caldier <i>First Reading (House):</i> 1/28/2025, referred to Health Care & Wellness Committee.
HB 1520	Pharmacists’ scope of practice	The bill would add a new section to chapter 18.64 RCW that allows pharmacists to prescribe certain categories of drugs including immunizations, antihistamine agents, hormonal contraception, and other medications used for the treatment of diseases, as well as drugs, drug categories, or devices that are limited to specified circumstances such as not requiring a new diagnosis or being minor and generally self-limiting in nature. The new section also has an expiration date of January 1, 2030. The definition for “practice of pharmacy” in RCW 18.64.011(32) is amended to include the diagnosing of conditions and diseases and the prescribing or ordering of drugs and devices as authorized by chapter 18.64 RCW and	HB 1520 <i>Sponsor(s):</i> Representatives Thai, Reed, Simmons, and Macri <i>First Reading (House):</i> 1/22/2025, referred to Health Care & Wellness Committee.

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
		<p>commission rules. The commission is also granted rulemaking authority to administer and implement the bill.</p> <p>RCW 69.41.030 is also amended to allow pharmacists to sell or deliver legend drugs “to the extent permitted under chapter 18.64 RCW” and removing the requirement to do so only through the creation and approval of “written guidelines or protocols” under RCW 18.64.011 and approved by a practitioner authorized to prescribe drugs.</p>	
<u>SB 5513</u>	Pharmacists’ scope of practice	Companion bill to HB 1520.	<p><u>SB 5513</u> <i>Sponsor(s):</i> Senators Slatter, Chapman, Nobles, and Short</p> <p><i>First Reading (Senate):</i> 1/27/2025, referred to Health & Long-Term Care Committee.</p>
<u>HB 1009</u>	Membership of the Pharmacy Quality Assurance Commission	HB 1009 amends RCW 18.64.001 pertaining to individual eligibility to apply for a seat on the Pharmacy Quality Assurance Commission (commission). The bill changes one of the seats reserved only for a licensed pharmacist to allow for a public member who “may be an owner, officer, or operator of a pharmacy, but may not be licensed as a pharmacist or pharmacy technician” to also apply for the seat.	<p><u>HB 1009</u> <i>Sponsor(s):</i> Representatives Low, Ramel, and Eslick</p> <p><i>Second Reading (Rules):</i> 1/28/2025; Rules Committee relieved of further consideration and placed on second reading</p> <p><i>Third Reading/Floor Vote (House):</i> 1/30/2025, passed through chamber by majority vote (96/0/0/2)</p>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
			<p><i>First Reading (Senate): 1/31/2025, referred to Health & Long-Term Care Committee.</i></p>
SHB 1186	Prepackaged medication distribution	<p>RCW 70.41.480(3) creates restrictions for a practitioner or registered nurse to distribute prepackaged emergency medications to patients upon discharge from an emergency department. Effective January 1, 2025, these restrictions include no more than a 48-hour supply that can be dispensed to a patient except when:</p> <ul style="list-style-type: none"> • community or hospital pharmacy services will not be available within 48 hours; or • human immunodeficiency virus postexposure prophylaxis (HIV PEP) drugs or therapies are required. <p>SHB 1186 amends these exceptions to include when anti-infective drugs or therapies are required or when drugs are packaged directly by the manufacturer in quantities larger than 48 hours (that cannot be altered down to a 48-hour supply), in addition to the above list.</p> <p>The bill also amends RCW 18.64.450 to allow health care entities (HCEs) to dispense and deliver legend drugs and controlled substances beyond the 72-hour limit in the following situations:</p> <ul style="list-style-type: none"> • Community or hospital outpatient pharmacy services will not be available within 72 hours; • Anti-infectives or human immunodeficiency virus postexposure prophylaxis (HIV PEP) drugs; or • Drugs or therapies packaged directly by the manufacturer for a period longer than a 72-hour period. 	<p>SHB 1186 <i>Sponsor(s):</i> Representatives Parshley, Rule, Low, Reed, Ramel, Macri, Obras, Farivar, Doglio, Fosse, Ormsby, Salahuddin, Bernbaum, and Hill</p> <p><i>Executive Session (Health Care & Wellness): 1/31/2025, substitute version introduced and voted by committee with a DO PASS recommendation; referred to Rules 2 Review (2/4).</i></p> <p><i>Second Reading (Rules): 2/11/2025</i></p>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
SB 5019	Prepackaged medication distribution	Companion bill to HB 1186.	<p>SB 5019 <i>Sponsor(s):</i> Senators Chapman, Bateman, Christian, Dhingra, Harris, Riccelli, Saldaña, Slatter, and Wellman</p> <p><i>First Reading (Senate):</i> 1/13/2025, referred to Health & Long-Term Care Committee.</p> <p><i>Public Hearing (Health & Long-Term Care):</i> 1/23/2025</p> <p><i>Executive Session (Health & Long-Term Care):</i> 2/6/2025, substitute version proposed, adopted, and passed through committee with a DO PASS recommendation; passed to Rules Committee for second reading (2/7).</p>
SB 5201	Access to psychedelic substances	<p>This bill establishes wellness model-based psilocybin services and establishes DOH and LCB authority to license, regulate, and enforce all provisions. Psilocybin can only be administered to a person 21 years of age or older in an approved setting, under the supervision of a licensed psilocybin facilitator or clinical facilitator. The program development period is designated from September 1, 2025 to September 1, 2027, during which DOH is to establish a Psychedelic Substances Board to advise DOH, conduct rulemaking, and establish educational trainings and exams.</p> <p>DOH must establish rules regarding qualifications, licensing and renewals, fees, education and training, substantially equivalent qualifications, testing, scope of practice, and other regulations specified in the bill for multiple new professions and facilities. DOH must also establish rules for defining “approved supervisor” qualification requirements, authorized disclosure of</p>	<p>SB 5201 <i>Sponsor(s):</i> Senators Salomon, Nobles, Bateman, Trudeau, Lovelett, Frame, Chapman, Hasegawa, Wellman, Holy, King, Saldaña, Schoesler, and J. Wilson</p> <p><i>Pre-filed:</i> 1/9/2025</p> <p><i>First Reading (Senate):</i> 1/13/2025, referred to Health & Long-Term Care Committee.</p> <p><i>Public Hearing (Health & Long-Term Care):</i> 2/6/2025</p> <p><i>Executive Session (Health & Long-Term Care):</i> 2/11/2025, proposed substitute</p>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
		protected client information, and other requirements outlined in the bill. Rules must be adopted and forms established by October 31, 2027. DOH must begin receiving applications November 1, 2027. “Psychedelic substance” is defined as psilocybin until the end of 2029.	posted but was not adopted by the committee; referred to Labor & Commerce.
HB 1433	Access to psychedelic substances	Companion bill to SB 5201.	HB 1433 <i>Sponsor(s):</i> Representatives Macri, Couture, Ramel, Griffey, Lekanoff, Ormsby, Nance, Walen, Cortes, Fosse, Doglio, Reeves, Goodman, McEntire, Bernbaum, Waters, Street, Pollet, Gregerson, Rude, Simmons, Berry, Fitzgibbon, Parshley, Peterson, Reed, Farivar, Tharinger, and Hill <i>First Reading (House):</i> 1/20/2025, referred to Health Care & Wellness Committee. <i>Public Hearing (Health Care & Wellness):</i> 2/5/2025, proposed substitute posted
SB 5713	Chemical abortion	This bill adds a new section to RCW 9.02 to include provisions related to patient anonymity in civil actions relating to chemical abortions. Other sections in chapter 9.02 are amended or created to include provisions to: <ul style="list-style-type: none"> • Remove exemptions from prosecution/penalties; • Create a requirement to provide written information to patients obtaining chemical abortions regarding liability; • Create a requirement that DOH prepare a reporting form for all 	SB 5713 <i>Sponsor(s):</i> Senator Fortunato <i>First Reading (Senate):</i> 2/10/2025, referred to Law & Justice Committee.

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
		<p>“abortion pill providers” and facilities;</p> <ul style="list-style-type: none"> • Create a requirement that DOH prepare a reporting form for all physicians or facilities that treat any adverse event or complication arising from a chemical abortion; • Create a \$500 per violation civil penalty for failing to complete the required reports; and • Create a cause of action for civil damages against a person who has performed or prescribed a chemical abortion for any patient who received a chemical abortion, the spouse of the patient, the parents of the patient if the patient is under 18, or the patient’s next of kin. 	
HB 1124	Psychologist prescriptive authority certification	HB 1124 amends chapter 18.83 RCW to establish a certification for prescribing psychologists. The bill authorizes prescribing psychologists to prescribe, administer, discontinue, and distribute controlled substances to treat mental illnesses. The bill also amends the definition of practitioner in RCW 18.64.011 to include prescribing psychologists.	<p>HB 1124 <i>Sponsor(s):</i> Representatives Simmons, Macri, Senn, Stonier, Ormsby, Tharinger, Kloba, Duerr, Ryu, Morgan, Reed, Callan, Obras, Doglio, Ortiz-Self, Goodman, Reeves, and Hill</p> <p><i>Pre-filed:</i> 12/23/2024 <i>First Reading (House):</i> 1/13/2025, referred to Health Care & Wellness Committee.</p>
SB 5112	Psychologist prescriptive authority certification	Companion bill to HB 1124.	<p>SB 5112 <i>Sponsor(s):</i> Senators Bateman, Harris, Shewmake, Trudeau, Conway, Nobles, Riccelli, C. Wilson, Robinson, and Hasegawa</p> <p><i>Pre-filed:</i> 12/23/2024</p>

Focus Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
			<p><i>First Reading (Senate): 1/13/2025, referred to Health & Long-Term Care Committee.</i></p> <p><i>Public Hearing (Health & Long-Term Care Committee): 2/13/2025</i></p>

Agency Request Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
<u>HB 1422</u>	Modifying the drug take-back program	<p>This bill amends various statutes in chapters 69.48 and 43.131 RCW relating to the drug take-back (i.e. safe medication return program) program. The bill expands the number of required elements that a program operator must submit via report to the department and updates the evaluation and approval standards for such reports.</p> <p>The bill further updates enforcement mechanisms if a program operator is out of compliance and allows the department to set an annual operating fee. A new section is also created in chapter 69.48 RCW to further outline the duties and responsibilities of a drug take-back program operator.</p>	<p><u>HB 1422</u> <i>Sponsor(s): Representatives Peterson, Davis, Thai, Ormsby, Hill, Macri, and Timmons</i></p> <p><i>First Reading (House): 1/20/2025, referred to Health Care & Wellness Committee.</i> <i>Public Hearing (Health Care & Wellness): 2/11/2025</i></p>

Agency Request Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
SB 5051	Consolidating regulatory authority for nursing assistants	This bill amends sections in chapters 18.79 and 18.88A RCW to consolidate the regulatory authority of nursing assistants under the Board of Nursing's jurisdiction.	<p>SB 5051 <i>Sponsor(s):</i> Senators Bateman, Riccelli, Cleveland, Nobles, and Wellman</p> <p><i>Second Reading (Rules):</i> 1/29/2025 <i>Third Reading/Floor Vote (Senate):</i> 2/7/2025, passed through chamber by majority vote (49/0/0/0).</p> <p><i>First Reading (House):</i> 2/11/2025, referred to Health Care & Wellness Committee.</p>
SB 5228	Governor's interagency coordinating council on health disparities updates	<p>This bill amends sections in chapter 43.20 RCW to update the description and composure of the coordinating council. Aside from updating definitions and making technical and grammatical fixes, the bill also amends RCW 43.20.275 to raise the number of seats to 24, including additional seats for public members and commission/committees such as the commission on African American affairs and the Governor's Committee on Disability Issues and Employment.</p> <p>RCW 43.20.280 is further amended to update the vision and goals of the council, public hearing and research requirements, and a deadline for the council's official report to the governor.</p>	<p>SB 5228 <i>Sponsor(s):</i> Senators Riccelli, Hasegawa, Conway, Nobles, and C. Wilson</p> <p><i>Pre-filed:</i> 1/10/2025 <i>First Reading (Senate):</i> 1/13/2025, referred to Health & Long-Term Care Committee. <i>Public Hearing (Health & Long-Term Care):</i> 1/24/2025</p>
SB 5244	WIC program staff exemptions for hematological screening tests	This bill adds a subsection to RCW 18.360.090 to include hematological tests and evaluations conducted by persons working at a special supplemental nutrition program for women, infants, and children (WIC) as exempt from other prohibitions or restrictions in chapter 18.360 RCW.	<p>SB 5244 <i>Sponsor(s):</i> Senators Riccelli, Bateman, Nobles, Saldaña, and C. Wilson</p>

Agency Request Bills			
Bill # /Companion	Short Title	Brief Description	Committee Action (subject to change)
			<p><i>Executive Session (Health & Long-Term Care): 1/24/2025; majority voted for DO PASS recommendation; passed to Rules Committee for second reading (1/27)</i></p> <p><i>Second Reading (Rules): 2/5/2025, placed on second reading consent calendar</i></p>

Additional Bills to Watch			
Bill # /Companion	Short Title		Committee Action (subject to change)
HB 1034	Nonopioid drugs for the treatment of pain	<u>HB 1034</u> <i>Sponsor(s):</i> Representatives Ortiz-Self, Peterson, Simmons, Kloba, Ormsby, Lekanoff, Donaghy, and Hill <i>Pre-filed:</i> 12/11/2024 <i>First Reading (House):</i> 1/13/2025, referred to Health Care & Wellness Committee. <i>Public Hearing (Health Care & Wellness):</i> 1/21/2025	
SHB 1209	Transfer of sodium nitrite	<u>HB 1209</u> <i>Sponsor(s):</i> Representatives Mena, Walen, Reed, Ryu, Berry, Alvarado, Macri, Farivar, Doglio, Pollet, Ormsby, Salahuddin, and Hill	

Additional Bills to Watch		
Bill # /Companion	Short Title	Committee Action (subject to change)
		<p><i>Third Reading/Floor Vote (House): 2/6/2025, 1st substitute version substituted and voted to pass through chamber (91/4/0/3)</i></p> <p><i>First Reading (Senate): 2/7/2025, referred to Business, Financial Services & Trade Committee.</i></p>
SB 5178	Transfer of sodium nitrite	<p>SB 5178 <i>Sponsor(s):</i> Senators Trudeau, Harris, Frame, Hasegawa, Lias, Nobles, Orwall, Pedersen, Salomon, and Shewmake</p> <p><i>Public Hearing (Business, Financial Services & Trade): 1/30/2025</i> <i>Executive Session (Business, Financial Services & Trade): 2/5/2025, voted through committee with a DO PASS recommendation, passed to Rules Committee for second reading (2/6)</i></p>
SB 5242	Interactive screening program for behavioral health service access	<p>SB 5242 <i>Sponsor(s):</i> Senators Orwall, Harris, Hasegawa, Krishnadasan, Nobles, Shewmake, Valdez, and C. Wilson</p> <p><i>First Reading (Senate): 1/14/2025, referred to Health & Long-Term Care Committee.</i> <i>Public Hearing (Health & Long-Term Care): 1/28/2025</i></p>
SB 5387	Corporate practice of medicine	<p>SB 5387 <i>Sponsor(s):</i> Senators Robinson, Hasegawa, Lias, Nobles, Riccelli, Stanford, and Valdez</p> <p><i>First Reading (Senate): 1/21/2025, referred to Health & Long-Term Care Committee.</i> <i>Public Hearing (Health & Long-Term Care): 2/7/2025</i></p>
HB 1675	Corporate practice of medicine	<p>HB 1675 <i>Sponsor(s):</i> Representatives Thai and Macri</p> <p><i>First Reading (House): 1/28/2025, referred to Health Care & Wellness Committee.</i></p>

Additional Bills to Watch		
Bill # /Companion	Short Title	Committee Action (subject to change)
SB 5452	Licensing psychiatric pharmacists as agency-affiliated counselors	<p>SB 5452 <i>Sponsor(s):</i> Senators Slatter and Nobles</p> <p><i>First Reading (Senate):</i> 1/23/2025, referred to Health & Long-Term Care Committee. <i>Public Hearing (Health & Long-Term Care):</i> 2/13/2025</p>

Dead/dormant Bills (relevant if needed to pass the budget)		
Bill # /Companion	Short Title	Bill Summary